Ibogaine in Florida: What the Law Says

Ibogaine treatment Florida is first a question about the law, and the official texts answer a narrow version of it: what is ibogaine's legal position in Florida? In the sources we read on 30 October 2026, ibogaine is a Schedule I controlled substance in both federal regulation and the Florida Statutes, and we did not find a Florida law or enacted bill that creates an ibogaine research program or an access pathway. This page explains what the texts say, what they do not say, and what we could not check. It is general information, not legal or medical advice, and it does not say whether any clinic or program is legal.

What federal law says

Ibogaine is listed as entry (d)(21) among the Schedule I hallucinogenic substances in 21 CFR 1308.11, and we found nothing showing it removed from that schedule.

What Florida law says

The 2026 Florida Statutes, section 893.03 defines Schedule I as a substance with a high potential for abuse and no currently accepted medical use in treatment in the United States, whose use under medical supervision does not meet accepted safety standards. Among the Schedule I hallucinogenic substances in subsection (1)(c), item 18 reads simply "Ibogaine."

Possession is addressed in section 893.13(6)(a). It says a person may not be in actual or constructive possession of a controlled substance unless it was lawfully obtained from a practitioner or under a valid prescription or order of a practitioner acting in the course of professional practice. A violation is a felony of the third degree. This page does not say how that wording applies to ibogaine, which is also federally Schedule I, or to any person's situation.

The Legislature does change the schedules. CS/SB 432 (2026), "Intoxicating Substances," became Chapter 2026-148 in June 2026 and takes effect on 1 October 2026 except as otherwise provided. Its summary says it excepts certain xylazine animal drug products from Schedule I. The summary does not mention ibogaine, but we did not read the full bill text.

What we did not find

We did not find a Florida statute or enacted bill specific to ibogaine research or access. That is different from Texas, whose 2025 law added a Chapter 491 to its Health and Safety Code for an ibogaine clinical-trial consortium. In the Florida texts we read, ibogaine appears in the controlled-substance schedule and nowhere else. A search for "ibogaine" on the Florida Senate's site returned no results we could read, and we could not search the Florida House's bill pages. That is not proof that no such bill exists, so check the current session's bill pages yourself.

Federal action in 2026

Executive Order 14401, signed on 18 April 2026, directs the FDA and the DEA to create a Right to Try pathway for psychedelic drugs, including ibogaine compounds; it is a directive to agencies, it does not name Florida, and we found no rule implementing it.

What this means for a person in Florida

Nothing we read in Florida's statutes creates a state route to ibogaine treatment, and the federal and state schedules both list the substance. Whether any research, physician or other arrangement is authorized in a particular case is a legal question we did not research. This page makes no statement about the law of other countries or about any clinic, and it cannot tell you whether something is lawful for you.

What to check

• The bill pages of the current Florida legislative session on flsenate.gov and flhouse.gov, because we could not search the House site and bills change.
• The current text of section 893.03 before relying on this page, because the Legislature amends it and effective dates differ.
• Whether a claim that something is "legal in Florida" names a statute and a date, and whether that statute says it.
• Whether a physician who knows your heart history has weighed in, because of the cardiac risk described below.
• Personal legal questions belong with a Florida lawyer, and health questions with a qualified physician.

Heart risk

A 2026 review in the journal Addiction describes a rare but clinically significant risk of prolonged QTc interval and potentially fatal ventricular arrhythmias with ibogaine, reports published cardiac events at therapeutic doses including in people with no known heart disease, and calls for treatment only under controlled medical supervision with close monitoring of heart function. The abstract does not say that any setting is safe, and neither does this page.

How this page was made

We read each source named here on 30 October 2026. The Florida statutes and bill page were read through automated summarizing fetches, and we read the federal regulation through a mirror because the official site blocks automated reading, so confirm each against the official text. We did not contact any agency, clinic or lawyer. Laws change, so check current sources before relying on this page.